Glimric-M3 Tablet SR is a fixed-dose combination oral antidiabetic medication containing Glimepiride 3mg and Metformin 500mg in a sustained-release formulation. This combination is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled on diet and exercise alone or those requiring dual therapy. Glimepiride, a sulfonylurea class agent, acts by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. The sustained-release formulation of Glimric-M3 ensures a gradual release of active ingredients, promoting better tolerability and reducing gastrointestinal side effects commonly associated with Metformin. This combination therapy offers complementary mechanisms of action, resulting in improved efficacy in lowering fasting and postprandial blood glucose levels. Glimric-M3 should be administered once daily with meals to optimize absorption and minimize adverse effects. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in cases of diabetic ketoacidosis, severe renal dysfunction, or hypersensitivity to its components.